Stockreport

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study [Yahoo! Finance]

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF Nucresiran is ALNY's next-generation RNAi therapeutic, which is being developed leveraging the company's proprietary IKARIA platform. The ongoing phase I study evaluat [Read more]